MedTrace Logo

Tofacitinib in Depression (TIDE)

NCT04141904 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-08-09

No results posted yet for this study

Summary

This study will test whether 7-10 day administration of the anti-inflammatory drug, tofacitinib, has positive effects on people experiencing treatment-resistant depression compared to placebo.

Conditions

Interventions

DRUG

Tofacitinib 5 MG [Xeljanz]

Tofacitinib 5mg capsules twice a day for 7-10 days

OTHER

Placebo

Placebo capsules twice a day for 7-10 days

Sponsors & Collaborators

Principal Investigators

  • Philip J Cowen · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-10
Primary Completion
2022-05-23
Completion
2022-05-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04141904 on ClinicalTrials.gov